FDA OK's Roche’s Ocrevus shorter 2-hour infusion for MS

 

• The FDA has approved Roche's (OTCQX:RHHBY) shorter two-hour infusion time for OCREVUS® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions.
• The EMA authorized the two-hour infusion time in May 2020 based on a positive opinion from the advisory group CHMP.
• OCREVUS is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal damage.
• https://seekingalpha.com/news/3644286-fda-oks-roche-s-ocrevus-shorter-2-hour-infusion-for-multiple-sclerosis